Clinical Trial Update: A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating irinotecan combined with dabrafenib and trametinib, plus anti-EGFR, as second-line therapy for metastatic colorectal cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Irinotecan (Irinotecan)
• Trametinib (trametinib)

Snippet

Sponsor: Blokhin's Russian Cancer Research Center | Conditions: Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING